Prevalence and antimicrobial susceptibility data for extended-spectrum β-lactamase– and AmpC-producing Enterobacteriaceae from the MYSTIC Program in Europe and the United States (1997–2004)

• Published in: Diagnostic microbiology and infectious disease Vol. 53; no. 4; pp. 257 - 264
• Main Authors: Goossens, Herman, Grabein, Béatrice
• Format: Journal Article
• Language: English
• Published: New York, NY Elsevier Inc 01-12-2005; Elsevier
• Subjects: AmpC; Anti-Bacterial Agents - pharmacology; Bacterial Proteins - biosynthesis; Bacteriology; beta-Lactamases - biosynthesis; Biological and medical sciences; Citrobacter; Citrobacter - drug effects; Citrobacter - enzymology; Drug Resistance, Bacterial; Enterobacter; Enterobacter - drug effects; Enterobacter - enzymology; Enterobacteriaceae; Enterobacteriaceae - drug effects; Enterobacteriaceae - enzymology; Enterobacteriaceae Infections - microbiology; Escherichia coli; Escherichia coli - drug effects; Escherichia coli - enzymology; Europe; Extended spectrum β-lactamases; Fundamental and applied biological sciences. Psychology; Humans; Infectious diseases; Klebsiella; Klebsiella - drug effects; Klebsiella - enzymology; Medical sciences; Meropenem; Microbial Sensitivity Tests; Microbiology; Miscellaneous; MYSTIC; Population Surveillance; United States; United States; North America; Europe; America; AmpC; Extended spectrum β-lactamases; Meropenem; MYSTIC; Enterobacteriaceae; Ampc; Prevalence; Microbiology; Extended-spectrum β-lactamase; Epidemiology; Infection; Antibiotic; Sensitivity resistance; Bacteria; Antibacterial agent
• ISSN: 0732-8893; 1879-0070
• DOI: 10.1016/j.diagmicrobio.2005.10.001

This article presents prevalence and susceptibility data from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Program in Europe (1997–2004) and the United States (1999–2004) for Enterobacteriaceae producing extended-spectrum β-lactamase (ESBL) and/or
AmpC β-lactamases. For ESBL-producing isolates, the prevalence of
Escherichia coli and
Klebsiella spp. in Europe and
Enterobacter spp. in the United States increased over time. For
AmpC-producing isolates, the prevalence of
Enterobacter spp. and
Citrobacter spp. decreased over time in Europe and the United States, respectively. Compared with other antimicrobial agents, meropenem and imipenem had greatest activity against ESBL-producing
E. coli and
Klebsiella spp. in both Europe (96.9–100.0%) and the United States (100.0%). Such activity was also found for
AmpC-producing Enterobacteriaceae in Europe (50.0–100.0%), and
Enterobacter spp. and
Citrobacter spp. from the United States (100.0% for both). The continued efficacy of carbapenems such as meropenem confirms that these remain first-line agents for treatment of nosocomial infections caused by Enterobacteriaceae-producing ESBL or
AmpC β-lactamases.